Preparation, Spectral Characterization and Biological Screening of new Azo Schiff base ligand and the Au (Iii) Complex as Anticancer

Abstract

Anew azo-Schiff base ligand 8-((Z)-(2-(€)-1-((4-hydroxy-3- methylphenyl) imino) ethyl) phenyl) diazenyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione, has been Preparation from reacting (Z)-8-((2-acetylphenyl) diazenyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione with 4-amino -2- methyl phenol. Anew series of complexes with Co (II), Ni (II), Cu (II), Zn (II), Hg (II), Cd(II), and Au(III) ions were prepared forming chelate complexes. Fourier-transform infrared spectroscopy (FTIR), proton nuclear magnetic resonance (1H-NMR) technique, ultraviolet visible spectroscopy (UV-Vis), mass analysis, molar conductance and magnetic susceptibility were used to characterize the structures of the new ligand and their transition metal complexes. The complexes were found to have the general formula [(M)(L)2] Cl2 where M = Co (II), Ni (II), Cu (II), Zn(II), Hg(II), and Cd(II), [(M)(L)Cl]Cl2 where M = Au(III), The FTIR results showed that the coordination sites were the azomethine nitrogen, imidazole ring nitrogen and azo nitrogen atoms of the azo-Schiff base ligand. The electronic spectral and magnetic measurement data indicated that the complexes exhibited octahedral geometry, except the Au (III) complex suggested a square planar geometry around the central metal ion. The biological activity results showed the highest inhibitory effect for gold the complex. In this study the cytotoxicity of Au (III) complex on human MCF-7 breast cancer and MCF-10A normal cells were MTT assay. The metal complexes showed selective cytotoxicity against breast cancer, this metal Complex excelled in halting proliferation of MCF-7 cancer cells with median inhibitory concentration (IC50) values of Au (III) complex. The results indicate undoubtedly the possibility of using them as antitumor drugs in the field of pharmacy breast cancer.